Investment Strategy
The fund management invests in global healthcare stocks that generate above-average and sustainable earnings growth over a long period of time. The fund focuses on companies that contribute to significantly improving human health, extending life expectancy and/or reducing healthcare costs. The long-term attractiveness of the healthcare sector is supported by demographics and social change due to the ageing population and rising wealth, especially in emerging countries.
- Investment in global stocks of any company size
- Portfolio of around 35 - 50 stocks
- Active and benchmark-agnostic approach
- Long-term investment horizon
Learn more about our investment philosophy in equity fund management
Further details on the opportunities and risks of this fund can be found in the sales prospectus.
Indexed performance
Performance in 12-month periods
Currencies
Sectors
Countries
Asset classes
Top Holdings
Monthly market comment
Equity markets had a strong start into the new year, but US politics remains an uncertainty factor. In January, the Berenberg Health Focus Fund outperformed its benchmark. Boston Scientific benefited from the fact that competitor J&J had to temporarily halt a competing product. Ambu appreciated significantly after the company reported good numbers. Intuitive Surgical reported strong quarterly numbers, which lifted its share price. Novo Nordisk's shares remained volatile in January and were unable to keep pace with the market. PolyPeptide was among the weaker performers due to concerns that the margin in 2025 could be lower than the market had expected. A relatively weak 2025 outlook weighed on Danaher's stock. We added Kuros, UCB and Dexcom Biosciences to the portfolio. We sold the small position in Edwards as we have a better alternative in the sub-segment with Abbott Laboratories. We also sold the remainder of our position in ICON. The outlook for 2025 was so broad that investors will monitor business performance for the time being.
Portfolio Management

Kay Eichhorn-Schott
Kay Eichhorn-Schott has been a Portfolio Manager at Berenberg since October 2017. Kay started his career in the Berenberg International Graduate Program in October 2015 and joined the Wealth and Asset Management division in London after completing the program. He holds a Master of Science in Finance and studied at EBS Business School, University of Bath and Texas A&M University. Kay Eichhorn-Schott is a CFA Charterholder.
CO₂-Intensity
The fund does not actively manage its carbon footprint, however, emissions data such as CO2 intensity are relevant parameters which can be used to assess the efficient management of a company and the extent of transition risks.
ESG Score
The data provider MSCI ESG uses an ESG score of 0 to 10 to assess the management of material ESG risks of portfolio holdings compared to competitors.
ESG Controversies Screen
Investments in the fund are monitored for ESG controversies and, with the help of MSCI ESG data, flagged according their severity. Thereby, potential ESG risks of investments are identified. In the case of an orange flag (severe controversy), we enter into an active exchange with the company. In the case of a red flag (very severe controversy), the company is excluded.